Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02852655 |
| Title | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase 0 |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | United States | Details | |
| University of California, San Francisco | San Francisco | California | 94143-0372 | United States | Details | |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | United States | Details | |
| Memorial Sloan-Kettering Cancer | New York | New York | 10065 | United States | Details | |
| UT, MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | United States | Details |